IP Library › Granted Patent US 12,304,945
Granted Patent B2
US 12,304,945 · App. 17/648,747 · Granted May 20, 2025

Engineered immunoglobulin heavy chain-light chain pairs and uses thereof

Inventors: Adam Louis Corper (Vancouver, CA); Dunja Urosev (Vancouver, CA); Stacey A. L. Tom-Yew (Coquitlam, CA); Dustin Weyland Blue Bleile (Vancouver, CA); Thomas Spreter Von Kreudenstein (Vancouver, CA); Surjit Dixit (Richmond, CA); Paula Irene Lario (South Vancouver, CA); Mario Sanches (Vancouver, CA)
Assignee: Zymeworks BC Inc.
C07K16/00C07K16/2863C07K16/32C07K16/36G16B40/00G16B40/10C07K2317/10C07K2317/31C07K2317/35C07K2317/51C07K2317/515C07K2317/52C07K2317/522C07K2317/524C07K2317/526C07K2317/53C07K2317/55C07K2317/72C07K2317/92C07K2317/94
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,304,945
App. No.
17/648,747
Granted
May 20, 2025
Kind
B2
Abstract

The present invention provides heterodimer pairs that can comprise a first heterodimer and a second heterodimer wherein each heterodimer comprises an immunoglobulin heavy chain or fragment thereof and an immunoglobulin light chain or fragment thereof. At least one of the heterodimers can comprise one or more amino acid modifications in the C H1 and/or C L domains, one or more amino acid modifications in the V H and/or V L domains, or a combination thereof. The modified amino acid(s) can be part of the interface between the light chain and heavy chain and are typically modified to create preferential pairing between each heavy chain and a desired light chain such that when the two heavy chains and two light chains of the heterodimer pair are co-expressed in a cell, the heavy chain of the first heterodimer preferentially pairs with one of the light chains rather than the other. Likewise, the heavy chain of the second heterodimer typically preferentially pairs with the second light chain rather than first.

Claims (47)

1. An isolated antigen binding polypeptide construct comprising at least a first heterodimer and a second heterodimer,

the first heterodimer comprising a first immunoglobulin G (IgG) heavy chain polypeptide sequence (H1) and a first immunoglobulin light chain polypeptide sequence (L1), and binding to a first epitope; and

the second heterodimer comprising a second immunoglobulin G (IgG) heavy chain polypeptide sequence (H2) and a second immunoglobulin light chain polypeptide sequence (L2), and binding to a second epitope,

wherein at least one of the H1 or L1 sequences of the first heterodimer is distinct from the corresponding H2 or L2 sequence of the second heterodimer, H1 and H2 each comprise a heavy chain variable domain (VH domain) and a heavy chain constant domain (CH1 domain), and L1 and L2 each comprise a light chain variable domain (VL domain) and a light chain constant domain (CL domain);

wherein H1 preferentially pairs with L1 as compared to L2, and H2 preferentially pairs with L2 as compared to L1;

wherein:

a) H1 comprises amino acid substitution 139W; L1 comprises amino acid substitution 116A, and L2 comprises amino acid substitution 135W;

b) H1 comprises amino acid substitution 139W; L1 comprises amino acid substitutions 116A and 135A; H2 comprises amino acid substitutions 139G and 145L and 179E and 190A, and L2 comprises amino acid substitutions 131R and 135W;

c) H1 comprises amino acid substitution 139W; L1 comprises amino acid substitutions 116S and 135A; H2 comprises amino acid substitutions 139G and 145L and 179E and 190A, and L2 comprises amino acid substitutions 131R and 135W;

d) H1 comprises amino acid substitution 139W; L1 comprises amino acid substitutions 116A and 135A; H2 comprises amino acid substitutions 139G and 190A, and L2 comprises amino acid substitutions 135W and 137A;

e) H1 comprises amino acid substitutions 37W and 139W; L1 comprises amino acid substitutions 98A and 116A and 135A; H2 comprises amino acid substitutions 37A and 103H and 139G and 190A, and L2 comprises amino acid substitutions 44W and 135W;

f) H1 comprises amino acid substitutions 37W and 103H and 139W; L1 comprises amino acid substitutions 98L and 116A and 135A; H2 comprises amino acid substitutions 139G and 190A, and L2 comprises amino acid substitutions 98W and 135W;

g) H1 comprises amino acid substitutions 39R and 139W; L1 comprises amino acid substitutions 38E and 116A and 135V; H2 comprises amino acid substitutions 39E and 139G and 190A, and L2 comprises amino acid substitutions 38R and 135W;

h) H1 comprises amino acid substitution 139W; L1 comprises amino acid substitutions 98W and 116A and 135A; H2 comprises amino acid substitutions 37W and 103H and 139G and 190A, and L2 comprises amino acid substitutions 98L and 135W;

i) H1 comprises amino acid substitutions 39R and 139W; L1 comprises amino acid substitutions 38D and 116A and 135A; H2 comprises amino acid substitutions 39D and 139G and 190A, and L2 comprises amino acid substitutions 38R and 135W;

j) H1 comprises amino acid substitutions 39D and 139W; L1 comprises amino acid substitution 38R and 116A and 135A; H2 comprises amino acid substitutions 39R and 139G and 190A, and L2 comprises amino acid substitutions 38D and 135W;

k) H1 comprises amino acid substitutions 139W and 145Y and 179E; L1 comprises amino acid substitution 116A and 131K and 135A; H2 comprises amino acid substitutions 139G and 190A, and L2 comprises amino acid substitution 135W, or

l) H1 comprises amino acid substitutions 139W and 186K; L1 comprises amino acid substitution 116A and 124E and 135A and 180E; H2 comprises amino acid substitutions 139G and 145T and 146G and 179E and 190A, and L2 comprises amino acid substitution 135W;

wherein when both L1 and L2 are co-expressed with at least one of H1 and H2, the amount of H1-L1 compared to H1-L2 and the amount of H2-L2 compared to H2-L1 is greater than the amount of H1-L1 compared to H1-L2 and the amount of H2-L2 compared to H2-L1 in the absence of the amino acid substitutions,

and wherein the numbering of amino acid residues is according to Kabat.

2. The antigen binding polypeptide construct of claim 1 , wherein H1 comprises amino acid substitution 139W; L1 comprises amino acid substitution 116A, and L2 comprises amino acid substitution 135W.

3. The antigen binding polypeptide construct of claim 1 , wherein H1, H2, L1 and L2 are co-expressed in a cell or H1, H2, L1 and L2 are co-expressed in a cell-free expression system.

4. The antigen binding polypeptide construct of claim 1 , wherein the first immunoglobulin light chain polypeptide sequence and/or the second immunoglobulin light chain polypeptide sequence is a kappa light chain polypeptide.

5. The antigen binding polypeptide construct of claim 1 , wherein the antigen binding polypeptide construct further comprises an Fc comprising two heavy chain constant domain polypeptides, each comprising a CH3 sequence, wherein the heavy chain polypeptides are coupled, with or without one or more linkers, to the first heterodimer and the second heterodimer.

6. The antigen binding polypeptide construct of claim 5 , wherein the Fc is a human Fc.

7. The antigen binding polypeptide construct of claim 6 , wherein the human Fc is a heterodimeric Fc.

8. The antigen binding polypeptide construct of claim 7 , wherein the human Fc comprises one or more modifications in at least one of the CH3 sequences that promote the formation of a heterodimeric Fc with stability comparable to a wild-type homodimeric Fc.

9. The antigen binding polypeptide construct of claim 8 , wherein:

a) one of the CH3 sequences comprises the amino acid substitutions L351Y, F405A, Y407V and the other comprises the amino acid substitutions T366L, K392M, T394W;

b) one of the CH3 sequences comprises the amino acid substitutions L351Y, F405A, Y407V and the other comprises the amino acid substitutions T366L, K392L, T394W;

c) one of the CH3 sequences comprises the amino acid substitutions T350V, L351Y, F405A, Y407V and the other comprises the amino acid substitutions T350V, T366L, K392M, T394W;

d) one of the CH3 sequences comprises the amino acid substitutions T350V, L351Y, F405A, Y407V and the other comprises the amino acid substitutions T350V, T366L, K392L, T394W; or

e) one of the CH3 sequences comprises the amino acid substitutions T350V, L351Y, S400E, F405A, Y407V and the other comprises the amino acid substitutions T350V, T366L, N390R, K392M, T394W,

wherein the numbering of amino acid residues of the CH3 sequences is according to the EU numbering system.

10. The antigen binding polypeptide construct of claim 9 , wherein the human Fc further comprises at least one CH2 sequence.

11. The antigen binding polypeptide construct of claim 10 , wherein the human Fc comprises one or more modifications to promote selective binding of Fc-gamma receptors.

12. The antigen binding polypeptide construct of claim 5 , wherein the one or more linkers are one or more polypeptide linkers, comprising one or more antibody hinge regions.

13. The antigen binding polypeptide construct of claim 1 , wherein the sequences of each of H1, H2, L1, and L2 are derived from human or humanized sequences.

14. The antigen binding polypeptide construct of claim 1 , wherein the antigen binding polypeptide construct is multi-specific or bispecific.

15. The antigen binding polypeptide construct of claim 5 , wherein the antigen binding polypeptide construct is conjugated to a therapeutic agent.

16. A pharmaceutical composition comprising the antigen binding polypeptide construct of claim 1 and a pharmaceutically acceptable carrier.

17. An isolated polynucleotide or set of isolated polynucleotides comprising at least one sequence that encodes the antigen binding polypeptide construct of claim 1 .

18. A vector or set of vectors comprising the isolated polynucleotide or set of isolated polynucleotides of claim 17 .

19. An isolated cell comprising the vector or set of vectors of claim 18 .

20. A method of obtaining an antigen binding polypeptide construct from the isolated cell of claim 19 , the method comprising the steps of:

(a) obtaining a host cell culture comprising the isolated cell comprising one or more nucleic acid sequences encoding the antigen binding polypeptide construct; and

(b) recovering the antigen binding polypeptide construct from the host cell culture.

Assignments (2)
CHANGE OF NAME Recorded Apr 21, 2023
From: ZYMEWORKS INC.
To: ZYMEWORKS BC INC.
Reel/Frame 063400/0372 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 8, 2022
From: SANCHES, MARIO; BLEILE, DUSTIN WEYLAND BLUE; LARIO, PAULA IRENE; CORPER, ADAM LOUIS; UROSEV, DUNJA; TOM-YEW, STACEY A.L.; SPRETER VON KREUDENSTEIN, THOMAS; DIXIT, SURJIT
To: ZYMEWORKS INC.
Reel/Frame 058927/0483 →
Priority Claims (1)
WO PCT/CA2013/050914 · Nov 28, 2013 · international
Continuity (7)
Division 16122417 · Sep 5, 2018
Division 14648222
Provisional Application 61730906 · Nov 28, 2012
Provisional Application 61761641 · Feb 6, 2013
Provisional Application 61818874 · May 2, 2013
Provisional Application 61869200 · Aug 23, 2013
Related Publication 20220227840A1 · Jul 21, 2022
References Cited (307)
US 5731168A · Carter et al. · 1998 [cited by applicant]
US 5807706A · Carter et al. · 1998 [cited by applicant]
US 5821333A · Carter et al. · 1998 [cited by applicant]
US 6809185B1 · Schoonjans et al. · 2004 [cited by applicant]
US 7183076B2 · Arathoon et al. · 2007 [cited by applicant]
US 7642228B2 · Carter et al. · 2010 [cited by applicant]
US 7695936B2 · Carter et al. · 2010 [cited by applicant]
US 7947271B2 · Browning et al. · 2011 [cited by applicant]
US 7951917B1 · Arathoon et al. · 2011 [cited by applicant]
US 8501185B2 · Heitner Hansen et al. · 2013 [cited by applicant]
US 8592562B2 · Kannan et al. · 2013 [cited by applicant]
US 9499634B2 · Dixit et al. · 2016 [cited by applicant]
US 9527927B2 · Chowdhury et al. · 2016 [cited by applicant]
US 9562109B2 · Von Kreudenstein et al. · 2017 [cited by applicant]
US 9574010B2 · Spreter Von Kreudenstein et al. · 2017 [cited by applicant]
US 9708388B2 · Dutalys · 2017 [cited by applicant]
US 9771573B2 · Corper et al. · 2017 [cited by applicant]
US 9914785B2 · Corper et al. · 2018 [cited by applicant]
US 10077298B2 · Corper · 2018 [cited by applicant]
US 10392438B2 · Bennett · 2019 [cited by applicant]
US 11078296B2 · Corper · 2021 [cited by applicant]
US 11161915B2 · Urosev et al. · 2021 [cited by applicant]
US 11286293B2 · Corper · 2022 [cited by applicant]
US 11306156B2 · Sanches · 2022 [cited by applicant]
US 20030003502A1 · Jardetzky et al. · 2003 [cited by applicant]
US 20030129659A1 · Whelihan et al. · 2003 [cited by applicant]
US 20050069549A1 · Herman · 2005 [cited by applicant]
US 20060074225A1 · Chamberlain et al. · 2006 [cited by applicant]
US 20060136184A1 · Gustafsson et al. · 2006 [cited by applicant]
US 20060160184A1 · Hoogenboom et al. · 2006 [cited by applicant]
US 20070196363A1 · Arathoon et al. · 2007 [cited by applicant]
US 20080050370A1 · Glaser et al. · 2008 [cited by applicant]
US 20090162360A1 · Klein et al. · 2009 [cited by applicant]
US 20090182127A1 · Kjaergaard et al. · 2009 [cited by applicant]
US 20090232811A1 · Klein et al. · 2009 [cited by applicant]
US 20090263392A1 · Igawa et al. · 2009 [cited by applicant]
US 20100015133A1 · Igawa et al. · 2010 [cited by applicant]
US 20100075326A1 · Jin et al. · 2010 [cited by applicant]
US 20100105874A1 · Schuurman et al. · 2010 [cited by applicant]
US 20100256338A1 · Brinkmann et al. · 2010 [cited by applicant]
US 20100286374A1 · Kannan et al. · 2010 [cited by applicant]
US 20100322934A1 · Imhof-Jung et al. · 2010 [cited by applicant]
US 20100322935A1 · Croasdale et al. · 2010 [cited by applicant]
US 20110008345A1 · Ashman et al. · 2011 [cited by applicant]
US 20110275787A1 · Kufer et al. · 2011 [cited by applicant]
US 20110287009A1 · Scheer et al. · 2011 [cited by applicant]
US 20110293613A1 · Brinkmann et al. · 2011 [cited by applicant]
US 20120143580A1 · Constantine et al. · 2012 [cited by applicant]
US 20120149876A1 · Von Kreudenstein et al. · 2012 [cited by applicant]
US 20120244578A1 · Kannan et al. · 2012 [cited by applicant]
US 20130078249A1 · Ast et al. · 2013 [cited by applicant]
US 20130195849A1 · Spreter Von Kreudenstein et al. · 2013 [cited by applicant]
US 20130336973A1 · Spreter Von Kreudenstein et al. · 2013 [cited by applicant]
US 20140051835A1 · Dixit et al. · 2014 [cited by applicant]
US 20140066599A2 · Blein et al. · 2014 [cited by applicant]
US 20140154254A1 · Kannan et al. · 2014 [cited by applicant]
US 20140187753A1 · Blein et al. · 2014 [cited by applicant]
US 20140200331A1 · Corper et al. · 2014 [cited by applicant]
US 20140370020A1 · Kuramochi et al. · 2014 [cited by applicant]
US 20150211001A1 · Ohrn et al. · 2015 [cited by applicant]
US 20150307594A1 · Corper et al. · 2015 [cited by applicant]
US 20160083480A1 · Ng et al. · 2016 [cited by applicant]
US 20160257763A1 · Von Kreudenstein et al. · 2016 [cited by applicant]
US 20170204199A1 · Sanches · 2017 [cited by examiner]
US 20180179296A1 · Corper et al. · 2018 [cited by applicant]
US 20190002589A1 · Bardroff et al. · 2019 [cited by applicant]
US 20190218311A1 · Loew et al. · 2019 [cited by applicant]
US 20190338048A1 · Urosev et al. · 2019 [cited by applicant]
US 20200087414A1 · Spreter Von Kreudenstein et al. · 2020 [cited by applicant]
US 20210355239A1 · Urosev · 2021 [cited by examiner]
US 20230192795A1 · Deak et al. · 2023 [cited by applicant]
US 20230265134A1 · Sivasubramanian · 2023 [cited by examiner]
CN 1176659 · 1998 [cited by applicant]
CN 102153650 · 2012 [cited by applicant]
CN 108283001A · 2018 [cited by applicant]
EP 1870459 · 2007 [cited by applicant]
EP 2543680A1 · 2013 [cited by applicant]
EP 2647707 · 2013 [cited by applicant]
JP 2012512894A · 2012 [cited by applicant]
JP 2012525149A · 2012 [cited by applicant]
JP 2018162253A · 2018 [cited by applicant]
WO 199404690 · 1994 [cited by applicant]
WO 199627011 · 1996 [cited by applicant]
WO 2006106905 · 2006 [cited by applicant]
WO 2007110205 · 2007 [cited by applicant]
WO 2009089004 · 2009 [cited by applicant]
WO 2010085682 · 2010 [cited by applicant]
WO 2010115553 · 2010 [cited by applicant]
WO 2011028952 · 2011 [cited by applicant]
WO 2011063348 · 2011 [cited by applicant]
WO 2011119484A1 · 2011 [cited by applicant]
WO 2011120134 · 2011 [cited by applicant]
WO 2011131746 · 2011 [cited by applicant]
WO 2011143545 · 2011 [cited by applicant]
WO 2011133886 · 2011 [cited by applicant]
WO 2011147982 · 2011 [cited by applicant]
WO 2012020096 · 2012 [cited by applicant]
WO 2012023053 · 2012 [cited by applicant]
WO 2012058768 · 2012 [cited by applicant]
WO 2012073985 · 2012 [cited by applicant]
WO 2012131555 · 2012 [cited by applicant]
WO 2012143523 · 2012 [cited by applicant]
WO 2012163519 · 2012 [cited by applicant]
WO 2013005194 · 2013 [cited by applicant]
WO 2013060867 · 2013 [cited by applicant]
WO 2013063702 · 2013 [cited by applicant]
WO 2013096291 · 2013 [cited by applicant]
WO 2014005784 · 2014 [cited by applicant]
WO 2014082179 · 2014 [cited by applicant]
WO 2014124326A1 · 2014 [cited by applicant]
WO 2014150973 · 2014 [cited by applicant]
WO 2015052230A1 · 2015 [cited by applicant]
WO 2015181805 · 2015 [cited by applicant]
WO 2016026943A1 · 2016 [cited by applicant]
WO 2016172485A2 · 2016 [cited by applicant]
WO 2017059551 · 2017 [cited by applicant]
WO 2017117179A1 · 2017 [cited by applicant]
WO 2018141894A1 · 2018 [cited by applicant]
WO 2018158719A1 · 2018 [cited by applicant]
RU2020112916, “Office Action”, Sep. 1, 2023, 27 pages. [cited by applicant]
JP2022-186638, “Office Action”, Oct. 25, 2023, 4 pages. [cited by applicant]
Berry, et al., “Substitution of Cysteine for Selenocysteine in Type I Iodothyronine Deiodinase Reduces the Catalytic Efficiency of the Protein but Enhances Its Translation”, Endocrinology, vol. 131, No. 4, Oct. 1992, pp… [cited by applicant]
Chen, et al., “Fusion Protein Linkers: Property, Design and Functionality”, Advanced Drug Delivery Reviews, vol. 65, No. 10, Oct. 15, 2013, pp. 1357-1369. [cited by applicant]
Halin, et al., “Synergistic Therapeutic Effects of a Tumor Targeting Antibody Fragment, Fused to Interleukin 12 and to Tumor Necrosis Factor Alpha”, Cancer Research, vol. 63, No. 12, Jun. 15, 2003, pp. 3202-3210. [cited by applicant]
Lund, et al., “Oligosaccharide-Protein Interactions in IgG can Modulate Recognition by Fcy Receptors”, The FASEB Journal, vol. 9, No. 1, Jan. 1995, pp. 115-119. [cited by applicant]
Maeda, et al., “Engineering of Functional Chimeric Protein Gvargula Luciferase”, Analytical biochemistry, vol. 249, No. 2, Jul. 1997, pp. 147-152. [cited by applicant]
Mariuzza, et al., “The Structural Basis of Antigen-Antibody Recognition”, Annual Review of Biophysics and Biophysical Chemistry, vol. 16, Jun. 1987, pp. 139-159. [cited by applicant]
Pan, et al., “Blocking Neuropilin-1 Function Has an Additive Effect with Anti-VEGF to Inhibit Tumor Growth”, Cancer Cell, vol. 11, No. 1, Jan. 2007, pp. 53-67. [cited by applicant]
Riechmann, et al., “Reshaping Human Antibodies for Therapy”, Nature, vol. 332, No. 6162, Mar. 24, 1988, pp. 323-327. [cited by applicant]
Su, et al., “The Role of Antibody Vk Framework 3 Region Towards Antigen Binding: Effects on Recombinant Production and Protein L Binding”, Scientific Reports, vol. 7, No. 1, Jun. 2017, pp. 1-7. [cited by applicant]
Vajdos, et al., “Comprehensive Functional Maps of the Antigen-Binding Site of an Anti-ErbB2 Antibody Obtained with Shotgun Scanning Mutagenesis”, Journal of Molecular Biology, vol. 320, No. 2, Jul. 5, 2002, pp. 415-428. [cited by applicant]
Singer et al., Genes and genomes; Two vols. V. 1, Moscow, “Mir”, 1998, p. 63. [cited by applicant]
Briney et al., Nature 566: 393 (Year: 2019). [cited by applicant]
Piche-Nicholas et al., MABS 10(1): 81-94 (Year: 2018). [cited by applicant]
Spiess et al., Molecular Immunology 67: 95-106 (Year: 2015). [cited by applicant]
U.S. Appl. No. 17/343,198; Non-Final Office Action dated Sep. 27, 2023. [cited by applicant]
U.S. Appl. No. 13/289,934, Advisory Action mailed on Feb. 5, 2016, 5 pages. [cited by applicant]
U.S. Appl. No. 13/289,934, Non-Final Office Action mailed on Feb. 27, 2015, 15 pages. [cited by applicant]
U.S. Appl. No. 13/289,934, Non-Final Office Action mailed on May 13, 2015, 17 pages. [cited by applicant]
U.S. Appl. No. 13/289,934, Notice of Allowance mailed on Apr. 25, 2016, 9 pages. [cited by applicant]
U.S. Appl. No. 13/289,934, Restriction Requirement mailed on Sep. 16, 2014, 6 pages. [cited by applicant]
U.S. Appl. No. 13/289,934, Final Office Action dated Nov. 16, 2015. [cited by applicant]
U.S. Appl. No. 13/289,934, Notice of Allowance dated Sep. 29, 2017. [cited by applicant]
U.S. Appl. No. 13/668,098, Final Office Action mailed on Nov. 17, 2015, 16 pages. [cited by applicant]
U.S. Appl. No. 13/668,098, Non-Final Office Action mailed on Apr. 3, 2015, 18 pages. [cited by applicant]
U.S. Appl. No. 13/668,098, Restriction Requirement mailed on Dec. 5, 2014, 10 pages. [cited by applicant]
U.S. Appl. No. 13/668,098, Notice of Allowance dated Sep. 23, 2016. [cited by applicant]
U.S. Appl. No. 13/892,198, Non-Final Office Action mailed on Oct. 6, 2015, 23 pages. [cited by applicant]
U.S. Appl. No. 13/892,198, Restriction Requirement mailed on Jul. 10, 2015, 12 pages. [cited by applicant]
U.S. Appl. No. 13/927,065, Non-Final Office Action mailed on Oct. 7, 2015, 10 pages. [cited by applicant]
U.S. Appl. No. 13/927,065, Final Office Action, Feb. 22, 2016. [cited by applicant]
U.S. Appl. No. 13/927,065, Notice of Allowance mailed on Aug. 26, 2016, 7 pages. [cited by applicant]
U.S. Appl. No. 13/927,065, Restriction Requirement mailed on Apr. 15, 2015, 9 pages. [cited by applicant]
U.S. Appl. No. 14/092,804, Restriction Requirement dated Jun. 18, 2015. [cited by applicant]
U.S. Appl. No. 14/092,804, Final Office Action mailed on Dec. 29, 2016, 46 pages. [cited by applicant]
U.S. Appl. No. 14/092,804, Non-Final Office Action mailed on Sep. 10, 2015, 33 pages. [cited by applicant]
U.S. Appl. No. 14/092,804, Restriction Requirement mailed on May 12, 2016, 5 pages. [cited by applicant]
U.S. Appl. No. 14/092,804, Notice of Allowance dated Nov. 1, 2017. [cited by applicant]
U.S. Appl. No. 14/432,153, Restriction Requirement mailed on Jun. 30, 2016, 7 pages. [cited by applicant]
U.S. Appl. No. 14/432,153, Non-Final Office Action issued Oct. 27, 2016. [cited by applicant]
U.S. Appl. No. 14/432,153, Notice of Allowance issued May 15, 2017. [cited by applicant]
U.S. Appl. No. 14/432,153, Corrected Notice of Allowance issued Aug. 18, 2017. [cited by applicant]
U.S. Appl. No. 14/648,222, Advisory Action mailed on Apr. 20, 2018, 3 pages. [cited by applicant]
U.S. Appl. No. 14/648,222, Final Office Action mailed on Dec. 29, 2017, 12 pages. [cited by applicant]
U.S. Appl. No. 14/648,222, Non-Final Office Action mailed on May 16, 2017, 43 pages. [cited by applicant]
U.S. Appl. No. 14/648,222, Notice of Allowance mailed on May 8, 2018, 7 pages. [cited by applicant]
U.S. Appl. No. 14/648,222, Restriction Requirement mailed on Dec. 2, 2016, 33 pages. [cited by applicant]
U.S. Appl. No. 14/648,222, Restriction Requirement mailed on May 9, 2016, 14 pages. [cited by applicant]
U.S. Appl. No. 15/355,019, Non-Final Office Action, Jul. 21, 2017. [cited by applicant]
U.S. Appl. No. 15/355,019, Notice of Allowance, Nov. 17, 2017. [cited by applicant]
U.S. Appl. No. 15/355,019, Notice of Allowance, May 22, 2018. [cited by applicant]
U.S. Appl. No. 15/355,019, Notice of Allowance, Jul. 29, 2019. [cited by applicant]
U.S. Appl. No. 15/355,019: Non-Final Office Action dated Jan. 8, 2019, 5 pages. [cited by applicant]
U.S. Appl. No. 15/409,456, Restriction Requirement dated Jan. 10, 2019. [cited by applicant]
U.S. Appl. No. 15/409,456, Non-Final Office Action dated May 23, 2019. [cited by applicant]
U.S. Appl. No. 15/409,456, Final Office Action dated Oct. 24, 2019. [cited by applicant]
U.S. Appl. No. 15/409,456, Final Office Action dated May 13, 2020. [cited by applicant]
U.S. Appl. No. 15/409,456, Notice of Allowance dated Aug. 27, 2020. [cited by applicant]
U.S. Appl. No. 15/411,799, Restriction Requirement dated Jan. 25, 2019. [cited by applicant]
U.S. Appl. No. 15/411,799, Notice of Allowance dated Jun. 10, 2019. [cited by applicant]
U.S. Appl. No. 15/896,170, Restriction Requirement dated Jun. 26, 2019. [cited by applicant]
U.S. Appl. No. 15/896,170, Office Action dated Sep. 18, 2019. [cited by applicant]
U.S. Appl. No. 15/896,170, Final Office Action dated May 18, 2020. [cited by applicant]
U.S. Appl. No. 15/896,170, Final Office Action dated Feb. 1, 2021. [cited by applicant]
U.S. Appl. No. 15/896,170, Notice of Allowance dated Mar. 30, 2021. [cited by applicant]
U.S. Appl. No. 15/896,170, Notice of Allowance dated Jun. 9, 2021. [cited by applicant]
U.S. Appl. No. 15/896,170, Supplemental Notice of Allowance dated Jun. 9, 2021. [cited by applicant]
U.S. Appl. No. 15/314,496, Corrected Notice of Allowance dated Jan. 27, 2022. [cited by applicant]
U.S. Appl. No. 15/314,496, Corrected Notice of Allowance dated Jan. 21, 2022. [cited by applicant]
U.S. Appl. No. 15/314,496, Notice of Allowance dated Dec. 6, 2021. [cited by applicant]
U.S. Appl. No. 15/314,496, Non-Final Office Action dated Mar. 30, 2021. [cited by applicant]
U.S. Appl. No. 15/314,496, Restriction Requirement dated May 8, 2018. [cited by applicant]
U.S. Appl. No. 15/314,496, Non-Final Office Action dated Oct. 17, 2018. [cited by applicant]
U.S. Appl. No. 15/314,496, Final Office Action dated Apr. 24, 2019. [cited by applicant]
U.S. Appl. No. 15/314,496, Office Action dated Jan. 6, 2020. [cited by applicant]
U.S. Appl. No. 15/314,496, Final Office Action dated Jul. 28, 2020. [cited by applicant]
U.S. Appl. No. 15/765,574, Restriction Requirement dated Sep. 10, 2019. [cited by applicant]
U.S. Appl. No. 15/765,574, Office Action dated Dec. 27, 2019. [cited by applicant]
U.S. Appl. No. 15/765,574, Notice of Allowance dated Sep. 2, 2020. [cited by applicant]
U.S. Appl. No. 16/122,417, Notice of Allowance dated Oct. 18, 2021. [cited by applicant]
U.S. Appl. No. 15/765,574, Notice of Allowance dated Jan. 27, 2021. [cited by applicant]
U.S. Appl. No. 15/765,574 Supplemental Notice of Allowability dated Apr. 26, 2021. [cited by applicant]
U.S. Appl. No. 16/568,611 Application submitted Sep. 12, 2019. [cited by applicant]
U.S. Appl. No. 17/107,217 Application submitted Nov. 30, 2020. [cited by applicant]
U.S. Appl. No. 16/122,417, Ex Parte Quayle dated Jul. 8, 2021. [cited by applicant]
U.S. Appl. No. 16/122,417, Final Office Action dated Feb. 9, 2021. [cited by applicant]
U.S. Appl. No. 16/122,417, Non-Final Office Action dated Jun. 19, 2020. [cited by applicant]
U.S. Appl. No. 16/122,417, Restriction Requirement dated Mar. 6, 2020. [cited by applicant]
U.S. Appl. No. 14/989,648, Heteromultimer Constructs of Immunoglobulin Heavy Chains With Mutations in the FC Domain filed on Jan. 6, 2016, 247 pages. [cited by applicant]
Altintas et al., Targeting Epidermal Growth Factor Receptor in Tumors: From Conventional Monoclonal Antibodies via Heavy Chain-only Antibodies to Nanobodies, Eur J Pharm Sci., vol. 45, No. 4, Mar. 12, 2012, pp. 399-407. [cited by applicant]
Atwell et al., Stable Heterodimers From Remodeling the Domain Interface of a Homodimer Using a Phage Display Library, Journal of Molecular Biology, vol. 270, Issue 1, Jul. 4, 1997, pp. 26-35. [cited by applicant]
Beck et al., Strategies and Challenges for the Next Generation of Therapeutic Antibodies, Nature Reviews Immunology, vol. 10, No. 5, May 2010, pp. 345-352. [cited by applicant]
Braden et al., FASEB J, 1995, vol. 9 (1), pp. 9-16. [cited by applicant]
Carter et al., Humanization of an Anti-p185HER2 Antibody for Human Cancer Therapy, Proc. Natl. Acad. Sci. USA, vol. 89, No. 10, 1992, pp. 4285-4289. [cited by applicant]
Carter, Introduction to Current and Future Protein Therapeutics: a Protein Engineering Perspective, Experimental Cell Research, vol. 317, No. 9, May 15, 2011, pp. 1261-1269. [cited by applicant]
Chames et al., Therapeutic Antibodies: Successes, Limitations and Hopes for the Future, British Journal of Pharmacology, vol. 157, No. 2, 2009, pp. 220-223. [cited by applicant]
Chen, Lei, et al., “Preferential Germline Usage and VH/VL Pairing Observed in Human Antibodies selected by mRNA display.”, Protein Engineering, Design & Selection: Peds, Oct. 2015, vol. 28, No. 10, pp. 427-435. [cited by applicant]
Colman, Effects of Amino Acid Sequence Changes on Antibody-antigen Interactions, Research in Immunology, vol. 145, No. 1, Jan. 1994, pp. 33-36. [cited by applicant]
Coloma et al., Design and Production of Novel Tetravalent Bispecific Antibodies, Nature Biotechnology, vol. 15, No. 2, Feb. 1997, pp. 159-163. [cited by applicant]
Dall'acqua et al., Contribution of Domain Interface Residues to the Stability of Antibody CH3 Domain Homodimers, Biochemistry, American Chemical Society, US, vol. 37, No. 26, Jun. 30, 1998, pp. 9266-9273. [cited by applicant]
Davis et al., SEEDbodies: Fusion Proteins Based on Strand-exchange Engineered Domain (SEED) CH3 Heterodimers in an Fc Analogue Platform for Asymmetric Binders or Immunofusions and Bispecific Antibodies, Protein Engineer… [cited by applicant]
Demarest et al., Antibody Therapeutics, Antibody Engineering, and the Merits of Protein Stability, Current Opinion in Drug Discovery and Development. vol. 11, No. 5, Sep. 2008, pp. 675-687. [cited by applicant]
Demarest et al., Optimization of the Antibody CH3 Domain by Residue Frequency Analysis of IgG Sequences, Journal of Molecular Biology, vol. 335, Issue 1, Jan. 2, 2004, pp. 41-48. [cited by applicant]
Dockal et al., Conformational Transitions of the Three Recombinant Domains of Human Serum Albumin Depending on pH, The Journal of Biological Chemistry, vol. 275, No. 5, Feb. 4, 2000, pp. 3042-3050. [cited by applicant]
Dockal et al., Five Recombinant Fragments of Human Serum Albumin-tools for the Characterization of the Warfarin Binding Site, Protein Science, vol. 9, No. 8, 2000, pp. 1455-1465. [cited by applicant]
Edwards, B.M., et al., The remarkable flexibility of the human antibody repertoire; isolation of over one thousand different antibodies to a single protein, BLyS. J. Mol. Biol. 2003; 334(1):103-118. [cited by applicant]
Feng, et al., “Dual function antibody drug substance research study progress”, Chin Med Biotechnol, Aug. 2014, vol. 9, No. 4., pp. 1-6. [cited by applicant]
Fischer, N., et al., Exploiting light chains for the scalable generation and platform purification or native human bispecific IgG. Nature Communications, Feb. 12, 2015; 6(6113):1-12. [cited by applicant]
Gramer, M. J., et al., Production of stable bispecific lgG1 by controlled Fab-arm exchange Scalability from bench to large-scale manufacturing by application of standard approaches. mAbs. Nov. 1, 2013;5(6):962-973. [cited by applicant]
Gunasekaran et al., Enhancing Antibody Fc Heterodimer Formation Through Electrostatic Steering Effects: Applications to Bispecific Molecules and Monovalent IgG, J. Biol. Chem., vol. 285, Issue 25, Jun. 18, 2010, pp. 196… [cited by applicant]
Hamel et al., The Role of the VL- and VH-Segments in the Preferential Reassociation of Immunoglobulin Subunits, Molecular Immunology, vol. 23, No. 5, May 23, 1986, pp. 503-510. [cited by applicant]
Heads, J.T., Relative stabilities of IgG1 and IgG4 Fab Domains: Influence of the Light-Heavy interchain disulfide bond architecture. Protein Science. Jul. 2012; 21(9):1315-1322. [cited by applicant]
Huang et al., A De Novo Designed Protein Interface, Protein Science, vol. 16, No. 12, 2007, pp. 2770-2774. [cited by applicant]
Igawa et al., VH/VL Interface Engineering to Promote Selective Expression and Inhibit Conformational Isomerization of Thrombopoietin Receptor Against Single-chain Diabody, Protein Engineering, Design & Selection, vol. 2… [cited by applicant]
Jackman et al., Development of a Two-part Strategy to Identify a Therapeutic Human Bispecific Antibody That Inhibits IgE Receptor Signaling, J Biol Chem., vol. 285, No. 27, Jul. 2, 2010, pp. 20850-20859. [cited by applicant]
Janeway et al., Structure of the Antibody Molecule and Immunoglobulin Genes, Immunology Third Edition, Garland Publishing Inc. Chapter 3, 1997, pp. 3:1-3:11. [cited by applicant]
Jordan et al., Structural Understanding of Stabilization Patterns in Engineered Bispecific Ig-like Antibody Molecules, Proteins: Structure, Function and Bioinformatics, vol. 77, No. 4, Dec. 1, 2009, pp. 832-841. [cited by applicant]
Klein et al., Progress in Overcoming the Chain Association Issue in Bispecific Heterodimeric LgG Antibodies, Mabs, vol. 4, No. 6, Nov. 2012, pp. 653-663. [cited by applicant]
Labrijin, A. F., et al., Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange. PNAS, Mar. 26, 2013; 110(13):5145-5150. [cited by applicant]
Lewis et al., Generation of Bispecific IgG Antibodies by Structure-Based Design of an Orthogonal Fab Interface, Nature Biotechnology, vol. 32, No. 2, Jan. 26, 2014, pp. 191-198. [cited by applicant]
Liu, Z., et al., A Novel Antibody Engineering Strategy for Making Monovalent Bispecific Heterodimeric IgG Antibodies by Electrostatic Steering Mechanism. Journal of Biological Chemistry. Mar. 2015; 290(12):7535-7562. [cited by applicant]
Lloyd, C., et al., Modelling the human immune response: performance of a 1011 human antibody repertoire against a broad panel of therapeutically relevant antigens. PEDS. 2009; 22(3):159-168. [cited by applicant]
Lu, D. et al., Fab-scFv Fusion Protein: an Efficient Approach to Production of Bispecific Antibody Fragments mailed on Journal of Immunological Methods, vol. 267, No. 2, 2002, pp. 213-226. [cited by applicant]
Maccallum et al., Antibody-Antigen Interactions: Contact Analysis and Binding Site Topography, Journal of Molecular Biology, vol. 262, No. 5, Oct. 1996, pp. 732-745. [cited by applicant]
Merchant et al., An Efficient Route to Human Bispecific IgG, Nature Biotechnology, vol. 16, No. 7, Jul. 16, 1998, pp. 677-681. [cited by applicant]
Merk et al., Cell-Free Expression of Two single-Chain Monoclonal Antibodies against Lysozyme: Effect of Domain Arrangement on the Expression, J. Biochem., vol. 125, Dec. 31, 1999, pp. 328-333. [cited by applicant]
Miller et al., Stability Engineering of scFvs for the Development of Bispecific and Multivalent Antibodies, Protein Engineering. Design and Selection, Oxford Journal, vol. 23, No. 7, Jul. 1, 2010, pp. 549-557. [cited by applicant]
Milstein et al., Hybrid Hybridomas and Their Use in Immunohistochemistry, Nature, vol. 305, No. 6, Oct. 6, 1983, pp. 537-540. [cited by applicant]
Moore et al., A Novel Bispecific Antibody Format Enables Simultaneous Bivalent and Monovalent Co-engagement of Distinct Target Antigens, mAbs, vol. 3, No. 6, 2011, pp. 546-557. [cited by applicant]
Omidfar et al., Studies of Thermostability in [cited by applicant]
Osborn et al., Pharmacokinetic and Pharmacodynamics Studies of a Human Serum Albumin-interferon-a Fusion Protein in Cynomolgus Monkeys, J. Pharamcology and Experiemental Therapeutics, vol. 330, Nov. 2002, pp. 540-548. [cited by applicant]
Padlan, E. A., et al., Antibody Fab assembly: The interface residues between CH1 and CL. Molecular Immunology, Sep. 1986; 23(9):951-960. [cited by applicant]
Paul, Protein and Polypeptide Antigenic Determinants, Fundamental Immunology, 3d ed., 1993, 1 page. [cited by applicant]
International Application No. PCT/IB2015/054107, International Search Report and Written Opinion mailed on Sep. 1, 2015, 19 pages. [cited by applicant]
International Application No. PCT/CA2013/050914, International Search Report and Written Opinion mailed on Feb. 7, 2014, 11 pages. [cited by applicant]
Portolano et al., Lack of Promiscuity in Autoantigen-Specific H and L Chain Combinations as Revealed by Human H and L Chain Roulette, J. Immunol., vol. 150, No. 3, Feb. 1, 1993, pp. 880-887. [cited by applicant]
Presta, et al., Engineering Therapeutic Antibodies for Improved Function, Biochem. Soc. Trans., vol. 30, No. 4, Aug. 2002, pp. 487-490. [cited by applicant]
Ridgway et al., Knobs-into-Holes' Engineering of Antibody CH3 Domains for Heavy Chain Heterodimerization, Protein Engineering, vol. 9, No. 7, Jul. 1996, pp. 617-621. [cited by applicant]
Rudikoff et al., Single Amino Acid Substitution Altering Antigen-Binding Specificity, Proc. Natl Acad Sci., vol. 79, No. 6, 1982, pp. 1979-1983. [cited by applicant]
Schaefer, W., et a., Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. PNAS, Jul. 5, 2011; 108(27):11187-11192. [cited by applicant]
Schlatter et al., On the Optimal Ratio of Heavy to Light Chain Genes for Efficient Recombinant Antibody Production by CHO Cells, Biotechnology Progress, vol. 21, No. 1, Jan.-Feb. 2005, pp. 122-133. [cited by applicant]
Segal et al., Introduction: Bispecific Antibodies, Journal of Immunological Methods, vol. 248, No. 1-2, Feb. 1, 2001, pp. 1-6. [cited by applicant]
Shields et al., High Resolution Mapping of the Binding Site on Human IgG1 for Fc Gamma RI, Fc Gamma RII, Fc Gamma RIll, and FcRn and Design of IgG1 Variants With Improved Binding to the Fc Gamma R, Journal of Biological… [cited by applicant]
Spreter Von Kreudenstein, T., et al., Improving biophysical properties of a bispecific antibody scaffold to aid developability. Sep./Oct. 2013, mAbs, vol. 5, No. 5, pp. 646-654. [cited by applicant]
Spreter Von Kreudenstein, T., et al., Protein engineering and the use of molecular modeling and simulation: the case of heterodimeric Fe engineering. Methods. Jan. 1, 2014; 65(1):77-94. [cited by applicant]
Stanglmaier et al., Bi20 (fBTA05), a Novel Trifunctional Bispecific Antibody (Anti-CD20 X Anti-CD3), Mediates Efficient Killing of B-cell Lymphoma Cells Even with Very Low CD20 Expression Levels, International Journal o… [cited by applicant]
Strop, P., et al., Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair. J Mol Biol. Jul. 13, 2012; 420(3):204-219. [cited by applicant]
Suresh et al., Bispecific Monoclonal Antibodies From Hybrid Hybridomas, Methods in Enzymology, vol. 121, 1986, pp. 210-228. [cited by applicant]
Tamaskovic et al., Designed Ankyrin Repeat Proteins (DARPins): From Reserach to Therapy, Methods in Enzymology, vol. 503, 2012, pp. 101-134. [cited by applicant]
Traunecker et al., Bispecific Single Chain Molecules (Janusins) Target Cytotoxic Lymphocytes on HIV Infected Cells, EMBO Journal, vol. 10, No. 12, Dec. 1991, pp. 3655-3699. [cited by applicant]
Verheesen et al., Selection by Phage Display of Single Domain Antibodies Specific to Antigens in Their Native Conformation, Methods Mo. Bio., Chapter 6, vol. 911, Jul. 12, 2012, pp. 81-104. [cited by applicant]
Von Kreudenstein et al., Improving Biophysical Properties of a Bispecific Antibody Scaffold to Aid Developability, MAbs, vol. 5, No. 5, Sep.-Oct. 2013, pp. 646-654. [cited by applicant]
Von Kreudenstein et al., Protein Engineering and the Use of Molecular Modeling and Simulation: The Case of Heterodimeric Fc Engineering, Methods, vol. 65, No. 1, Jan. 1, 2014, pp. 77-94. [cited by applicant]
Wiens et al., Mutation of a Single Conserved Residue in VH Complementarity-determining Region 2 Results in a Severe Ig Secretion Defect., J. Immunology, vol. 167, No. 4, Aug. 2001, pp. 2179-2186. [cited by applicant]
Wu et al., Humanization of a Murine Monoclonal Antibody by Simultaneous Optimization of Framework and CDR Residues, Journal of Molecular Biology, vol. 294, Nov. 1999, pp. 151-162. [cited by applicant]
Zhu et al., Remodeling Domain Interfaces to Enhance Heterodimer Formation, Protein Science, vol. 6, No. 4, Apr. 1997, pp. 781-788. [cited by applicant]
U.S. Appl. No. 17/241,181, “Final Office Action”, Jan. 5, 2024, 6 pages. [cited by applicant]
U.S. Appl. No. 17/241,181, “Final Office Action”, Sep. 6, 2024, 9 pages. [cited by applicant]
U.S. Appl. No. 17/241,181, “Non-Final Office Action”, Feb. 27, 2024, 12 pages. [cited by applicant]
U.S. Appl. No. 17/241,181, “Non-Final Office Action”, Jan. 7, 2025, 14 pages. [cited by applicant]
U.S. Appl. No. 17/241,181, “Non-Final Office Action”, Aug. 10, 2023, 9 pages. [cited by applicant]
U.S. Appl. No. 17/652,557, “Final Office Action”, Oct. 25, 2024, 9 pages. [cited by applicant]
U.S. Appl. No. 17/652,557, “Non-Final Office Action”, Jun. 3, 2024, 10 pages. [cited by applicant]
U.S. Appl. No. 17/652,557, “Notice of Allowance”, Jan. 17, 2025, 9 pages. [cited by applicant]
Arnau et al., “Current Strategies for the Use of Affinity Tags and Tag Removal for the Purification of Recombinant Proteins”, Protein Expression and Purification, vol. 48, No. 1, Jul. 2006, pp. 1-13. [cited by applicant]
Deyev et al., “Modern Technologies for Creating Synthetic Antibodies for Clinical Application”, Acta Naturae, vol. 1, No. 1, Apr. 2009, pp. 32-50. [cited by applicant]
Dufner et al., “Harnessing Phage and Ribosome Display for Antibody Optimisation”, Trends in Biotechnology, vol. 24, No. 11, 2006, pp. 523-529. [cited by applicant]
Feng et al., “Research Progress of Bifunctional Antibody Drugs”, Chinese Medical Biotechnology, vol. 9, No. 4, Aug. 31, 2014, pp. 291-293. [cited by applicant]
Gasser et al., “Antibody Production with Yeasts and Filamentous Fungi: on the Road to Large Scale?”, Biotechnology Letters, vol. 29, No. 2, Mar. 2007, pp. 201-212. [cited by applicant]
Ionescu et al., “Contribution of Variable Domains to the Stability of Humanized IgG1 Monoclonal Antibodies”, Journal of Pharmaceutical Sciences, vol. 97, No. 4, Apr. 2008, pp. 1414-1426. [cited by applicant]
Jaeger, “Clinical Immunology and Allergology”, Medicine, Second Edition, vol. 2, 1990, pp. 484-485. [cited by applicant]
Kabat et al., “Sequences of Proteins of Immunological Interest”, Diane Publishing, Fifth Edition, NIH Publication No. 91-3242, 1992, 11 pages. [cited by applicant]
Kaloff et al., “Coordination of Immunoglobulin Chain Folding and Immunoglobulin Chain Assembly is Essential for the Formation of Functional IgG”, Immunity, vol. 2, Jun. 1995, pp. 629-637. [cited by applicant]
Klein et al., “The Use of CrossMAb Technology for the Generation of bi- and Multispecific Antibodies”, Monoclonal Antibody, vol. 8, No. 6, Jun. 10, 2016, pp. 1010-1020. [cited by applicant]
Kolfschonten et al., “Anti-Inflammatory Activity of Human lgG4 Antibodies by Dynamic Fab Arm Exchange”, Science, vol. 317, No. 5844, Sep. 14, 2007, pp. 1554-1557. [cited by applicant]
Lehmann et al., “Stability Engineering of Anti-EGFR SCFV Antibodies By Rational Design of A Lambda-To-Kappa Swap of the VL Framework Using A Structure-Guided Approach”, Monoclonal Antibodies, vol. 7, No. 6, Nov.-Dec. 20… [cited by applicant]
Martin, “Protein Sequence and Structure Analysis of Antibody Variable Domains”, Antibody Engineering, vol. 2, Jan. 2010, pp. 33-51. [cited by applicant]
Mccann et al., “Peptide Tags for Labeling Membrane Proteins in Live Cells with Multiple Fluorophores”, Bio Techniques, vol. 38, No. 6, Jun. 2005, pp. 945-951. [cited by applicant]
Pakula et al., “Genetic Analysis of Protein Stability and Function”, Annual Reviews of Genetics, vol. 23, No. 1, Dec. 1989, pp. 289-310. [cited by applicant]
Rossi et al., “Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting”, Proceedings of the National Academy of Sciences 103.18 (2006), 6841-6846. [cited by applicant]
Safdari et al., “Antibody Humanization Methods—A Review and Update”, Biotechnology and Genetic Engineering Reviews, vol. 29, No. 2, Aug. 2013, pp. 175-186. [cited by applicant]
Shen et al., “Single Variable Domain-IgG Fusion a Novel Recombinant Approach to Fc Domain-Containing Bispecific Antibodies”, Journal of Biological Chemistry, vol. 281, No. 16, Feb. 2006, pp. 10706-10714. [cited by applicant]
Tao et al., “Biochemistry”, World Publishing Xi'an Co., Ltd., Aug. 31, 2010, p. 234. [cited by applicant]
Torres et al., “The Immunoglobulin Constant Region Contributes to Affinity and Specificity”, Trends in Immunology, vol. 29, No. 2, Feb. 2008, pp. 91-97. [cited by applicant]
Tu et al., “Generation and Characterization of Chimeric Antibodies against NS3, NS4, NS5, and Core Antigens of Hepatitis C Virus”, Clinical & Vaccine Immnology, vol. 17, No. 6, Jun. 2010, pp. 1040-1047. [cited by applicant]
Yarilin, “Fundamentals of Immunology”, Textbooks for Medical Students, M.: Medicine, 1999, pp. 172-174. [cited by applicant]
Zhu et al., “Engineering High Affinity Humanized Anti-P185her2/Anti-CD3 Bispecific F(Ab')2 For Efficient Lysis of P185her2 Overexpressing Tumor Cells”, International Journal of Cancer, vol. 63, No. 3, 1995, 1 page. [cited by applicant]